|
| related topics |
| {product, liability, claim} |
| {product, candidate, development} |
| {property, intellectual, protect} |
| {product, market, service} |
| {regulation, government, change} |
| {tax, income, asset} |
| {personnel, key, retain} |
| {stock, price, operating} |
| {operation, international, foreign} |
| {customer, product, revenue} |
|
|
OUR PRODUCTS MUST GAIN MARKET ACCEPTANCE FOR US TO INCREASE REVENUE.
OUR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS MAY NOT SUCCEED OR OUR COMPETITORS MAY DEVELOP AND COMMERCIALIZE MORE EFFECTIVE OR SUCCESSFUL DIAGNOSTIC PRODUCTS.
IF WE FAIL TO OBTAIN OR MAINTAIN THE REGULATORY APPROVALS NECESSARY TO SELL OUR PRODUCTS, SALES COULD BE NEGATIVELY IMPACTED.
IF WE DO NOT MATCH OUR PRODUCT MANUFACTURING CAPABILITY TO CUSTOMER DEMAND IN A COST-EFFECTIVE MANNER, OUR PRODUCT SALES MAY SUFFER.
OUR BUSINESS COULD SUFFER IF WE CANNOT ATTRACT, RETAIN AND MOTIVATE SKILLED PERSONNEL.
IT IS DIFFICULT AND COSTLY TO PROTECT OUR INTELLECTUAL PROPERTY RIGHTS, AND WE CANNOT ENSURE THE PROTECTION OF THESE RIGHTS; WE MAY BE SUED BY OTHERS FOR INFRINGING THEIR INTELLECTUAL PROPERTY RIGHTS.
IF PRODUCT LIABILITY LAWSUITS ARE SUCCESSFULLY BROUGHT AGAINST US, WE MAY INCUR SUBSTANTIAL LIABILITIES AND MAY HAVE TO LIMIT OR CEASE COMMERCIALIZATION OF OUR PRODUCTS.
IF OUR COMPANY DOES NOT PRODUCE FUTURE TAXABLE INCOME, OUR ABILITY TO REALIZE THE BENEFITS OF DEFERRED TAX ASSETS COULD BE IMPAIRED.
OUR RESULTS OF OPERATIONS MAY FLUCTUATE, WHICH COULD CAUSE VOLATILITY IN OUR STOCK PRICE.
WE MAY BE LIABLE FOR DAMAGES.
OUR ANTIBODY PRODUCTION PROCESS UTILIZES VARIOUS SPECIES OF ANIMALS THAT COULD CONTRACT DISEASE OR DIE, INTERRUPTING BUSINESS OPERATIONS.
THE DIFFICULTIES OF OPERATING IN INTERNATIONAL MARKETS MAY HARM SALES OF OUR PRODUCTS.
Full 10-K form ▸
|
|
| related documents |
| 911649--3/31/2006--STRATEGIC_DIAGNOSTICS_INC/DE/ |
| 27096--9/13/2006--DATASCOPE_CORP |
| 27096--9/12/2007--DATASCOPE_CORP |
| 780127--1/12/2006--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 880432--9/28/2009--MISONIX_INC |
| 764579--3/19/2008--CAS_MEDICAL_SYSTEMS_INC |
| 9892--2/27/2007--BARD_C_R_INC_/NJ/ |
| 9892--2/23/2006--BARD_C_R_INC_/NJ/ |
| 780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 9892--2/26/2008--BARD_C_R_INC_/NJ/ |
| 718924--12/27/2006--SPAN_AMERICA_MEDICAL_SYSTEMS_INC |
| 8146--4/16/2008--ASTRO_MED_INC_/NEW/ |
| 880432--9/28/2007--MISONIX_INC |
| 894237--6/29/2006--VISION_SCIENCES_INC_/DE/ |
| 768408--6/24/2010--CYANOTECH_CORP |
| 10456--2/26/2008--BAXTER_INTERNATIONAL_INC |
| 9892--2/26/2009--BARD_C_R_INC_/NJ/ |
| 1114200--2/27/2008--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 10456--3/7/2006--BAXTER_INTERNATIONAL_INC |
| 862668--10/12/2010--ESCALON_MEDICAL_CORP |
| 880432--9/26/2008--MISONIX_INC |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 1006195--3/15/2007--MATRIXX_INITIATIVES_INC |
| 862668--9/29/2008--ESCALON_MEDICAL_CORP |
| 57528--2/22/2008--LANCE_INC |
| 874734--3/8/2010--OSTEOTECH_INC |
| 1032863--3/16/2007--FORCE_PROTECTION_INC |
| 739944--3/10/2009--MEDTOX_SCIENTIFIC_INC |
| 1005010--3/24/2006--ARTHROCARE_CORP |
| 16732--10/11/2006--CAMPBELL_SOUP_CO |
|